Updated:
Assay Depot
Kevin Lustig's Assay Depot family office deploys capital from the sale of his drug discovery marketplace into life-science tech and biotech.
Assay Depot
Kevin Lustig founded Assay Depot Inc. in 2007, an online marketplace connecting researchers with contract research organizations. The platform was acquired by an undisclosed buyer in 2019, generating the family capital now managed through Assay Depot, the family office based in Solana Beach, California. The office deploys capital across life-science software, digital health, and early-stage biotech. Known investments include a stake in BioBright, a platform for lab data integration later acquired by Dotmatics, and support for Transcriptic (now Strateos), a robotic cloud lab provider. Geographic focus is North America, with select European co-investments. Team size and total deployment are not publicly disclosed. No additional offices or philanthropic vehicles are known publicly. Assay Depot's limited public footprint suggests a lean operation focused on direct investments rather than fund commitments. A structural differentiator is the operating-company pedigree: Lustig built a marketplace that aggregated fragmented CRO services, giving the office domain expertise in life-science R&D bottlenecks. The mandate likely targets companies digitizing or automating aspects of drug development, an area where the founder has direct operational experience.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Solana Beach
Corporate office
Solana Beach, CA, United States
Principals
Kevin Lustig
Founder
Sector focus
Frequently asked questions
Who runs Assay Depot?
Kevin Lustig founded Assay Depot Inc. in 2007 and now runs the family office. He previously served as CEO of the company and holds a PhD in neuroscience from the University of Michigan (per LinkedIn).
What investment stages does Assay Depot target?
Based on known activities, the office targets early-stage venture investments, particularly seed and Series A rounds in life-science software and biotech. No public evidence of later-stage or public equity investing.
How does Assay Depot source deal flow?
The office likely leverages Kevin Lustig's network from building Assay Depot Inc., including relationships with CROs, academic labs, and life-science entrepreneurs. No co-investor club or formal sourcing program is publicly known.
Is Assay Depot a single family office or a multi-family office?
Public records indicate Assay Depot operates as a single family office for Kevin Lustig and his family. No evidence of outside client capital.
Does Assay Depot participate in fund commitments or only direct deals?
Available information suggests Assay Depot primarily makes direct investments in private companies. There is no public record of limited partner commitments to external venture funds.
Where does the underlying wealth come from?
The wealth originates from the acquisition of Assay Depot Inc., the online CRO marketplace Lustig founded, though the acquirer and terms have not been publicly disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: